Trial Profile

A confirmatory phase 3 trial of Izokibep in Subjects With Moderate to Severe Hidradenitis Suppurativa

Status: Planning

Phase of Trial: Phase III

Latest Information Update: 30 Jun 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Izokibep (Primary)
Indications Hidradenitis suppurativa
Focus Registrational; Therapeutic Use

Most Recent Events

21 May 2025 According to a Alumis media release, Alumis Inc. merged with ACELYRIN, Inc. and subsequently changed its name to Alumis Inc.
13 Mar 2024 New trial record
11 Mar 2024 According to an ACELYRIN Media Release, this phase 3 trial is planned to address guidance on size of safety database given the FDA no longer considers moderate-to-severe HS an orphan disease.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com